Results 181 to 190 of about 93,504 (350)

Drug–Drug Interactions of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone With Midazolam, Warfarin, and Digoxin: A Phase 1 Studies in Healthy Volunteers

, 2020
Tadakatsu Nakamura, H. Shimizu, Atsuhiro Kawaguchi   +2 more
openalex   +1 more source

Modulation of Immunity and Inflammation by the Mineralocorticoid Receptor and Aldosterone [PDF]

, 2015
Natalia Muñoz‐Durango, Andrea Vecchiola, Luis M González-Gómez, Felipe Simón, Claudia A. Riedel, Carlos Fardella, Alexis M. Kalergis   +6 more
openalex   +1 more source

Literature‐informed ensemble machine learning for three‐year diabetic kidney disease risk prediction in type 2 diabetes: Development, validation, and deployment of the PSMMC NephraRisk model

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Introduction Diabetic kidney disease (DKD) and diabetic nephropathy (DN) affect around 40% of diabetic patients but lack accurate risk prediction tools that include social determinants and demographic complexity. We developed and validated an ensemble machine learning model for three‐year DKD/DN risk prediction with deployment readiness ...
Ayla M. Tourkmani, Turki J. Al‐Harbi, Ahmad Abdullah Alghamdi, Ibrahim M. Youzghadli, Faris Saad Alosaimi, Ahmed Y. Azzam   +5 more
wiley   +1 more source

Overexpression of mineralocorticoid receptors does not affect memory and anxiety-like behavior in female mice [PDF]

, 2015
Sofia Kanatsou, Laura E. Kuil, Marit Arp, Melly S. Oitzl, Anjanette Harris, Jonathan R. Seckl, Harm J. Krugers, Marian Joëls   +7 more
openalex   +1 more source

Diabetic kidney disease, biomarkers, and finerenone

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Diabetic kidney disease (DKD), the leading cause of kidney failure worldwide, is associated with an increased risk of cardiovascular disease (CVD). A complex pathobiology involving hemodynamic, metabolic, and immune dysregulation promotes inflammatory and fibrotic pathways that contribute to kidney disease progression and CVD in individuals ...
Ashish Verma, Ashish Upadhyay
wiley   +1 more source

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Toshiyuki Ko, Kazuki Aoyama, Takashin Nakayama, Yuya Kimura, Katsuhiko Fujiu, Norifumi Takeda, Hiroyuki Morita, Takashi Yokoo, Koichi Node, Masaomi Nangaku, Norihiko Takeda, Hideo Yasunaga, Kaori Hayashi   +16 more
wiley   +1 more source

Randomized Controlled Trial of Mineralocorticoid Receptor Blockade in Children with Chronic Kidney Allograft Nephropathy [PDF]

, 2017
Mara Medeiros-Domingo, L Velásquez-Jones, Ana M Guerreiro Hernández, Guillermo Ramón-Garcı́a, Saúl Valverde, Yolanda Fuentes, Arindal Vargas, Mauricio Patiño, Rosalba Pérez‐Villalva, Juan Antonio Ortega-Trejo, Jonatan Barrera‐Chimal, Norma A. Bobadilla   +11 more
openalex   +1 more source

Phenotyping of acute heart failure with preserved ejection fraction: real‐world outcomes in a cohort of older patients

Internal Medicine Journal, EarlyView.
Abstract Background Previous studies have identified distinct subgroups (phenogroups) of patients with heart failure with preserved ejection fraction (HFpEF). Aims This study aims to identify distinct phenotypes in older patients with HFpEF hospitalised for acute heart failure (AHF) and investigate the relationship between subgroups and outcomes ...
Maria Livia Burzo *, Giuseppe De Matteis, Amato Serra, Davide Antonio Della Polla, Mariella Fuorlo, Maria Anna Nicolazzi, Benedetta Simeoni, Antonio Gasbarrini, Francesco Franceschi, Giovanni Gambassi, Marcello Covino   +10 more
wiley   +1 more source

A COMPARATIVE ASSESSMENT OF THE EFFECT OF MINERALOCORTICOID RECEPTOR ANTAGONISTS ON CHANGES IN GALECTIN-3 AND MMP-1 FIBROSIS MARKERS IN PATIENTS WITH CHRONIC CARDIAC FAILURE COMBINED WITH TYPE 2 DIABETES MELLITUS WITH MANIFESTATIONS OF MYOCARDIUM DYSSYNCHRONY

Journal of V. N. Karazin Kharkiv National University: Series Medicine, 2016
A comparative assessment of the effect of mineralocorticoid receptor antagonists on changes in galectin 3 and matrix metalloproteinase 1 fibrosis markers has been carried out on 106 examinations (average age (69 + 10.37) years) with type 2 DM and CCF of ...
T. A. Rudenko
doaj  

Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.

Kidney International, 2019
J. Barrera-Chimal, S. Girerd, F. Jaisser
semanticscholar   +1 more source